Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial

S. Halvorsen, D. Atar, H. Yang, R. De Caterina, C. Erol, D. Garcia, CB. Granger, M. Hanna, C. Held, S. Husted, EM. Hylek, P. Jansky, RD. Lopes, W. Ruzyllo, L. Thomas, L. Wallentin,

. 2014 ; 35 (28) : 1864-72.

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu srovnávací studie, časopisecké články, multicentrická studie, randomizované kontrolované studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc15023566

AIMS: The risk of stroke in patients with atrial fibrillation (AF) increases with age. In the ARISTOTLE trial, apixaban when compared with warfarin reduced the rate of stroke, death, and bleeding. We evaluated these outcomes in relation to patient age. METHODS AND RESULTS: A total of 18 201 patients with AF and a raised risk of stroke were randomized to warfarin or apixaban 5 mg b.d. with dose reduction to 2.5 mg b.d. or placebo in 831 patients with ≥2 of the following criteria: age ≥80 years, body weight ≤60 kg, or creatinine ≥133 μmol/L. We used Cox models to compare outcomes in relation to patient age during 1.8 years median follow-up. Of the trial population, 30% were <65 years, 39% were 65 to <75, and 31% were ≥75 years. The rates of stroke, all-cause death, and major bleeding were higher in the older age groups (P < 0.001 for all). Apixaban was more effective than warfarin in preventing stroke and reducing mortality across all age groups, and associated with less major bleeding, less total bleeding, and less intracranial haemorrhage regardless of age (P interaction >0.11 for all). Results were also consistent for the 13% of patients ≥80 years. No significant interaction with apixaban dose was found with respect to treatment effect on major outcomes. CONCLUSION: The benefits of apixaban vs. warfarin were consistent in patients with AF regardless of age. Owing to the higher risk at older age, the absolute benefits of apixaban were greater in the elderly.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc15023566
003      
CZ-PrNML
005      
20150729121927.0
007      
ta
008      
150709s2014 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1093/eurheartj/ehu046 $2 doi
035    __
$a (PubMed)24561548
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Halvorsen, Sigrun $u Department of Cardiology B, Oslo University Hospital, Oslo 0407, Norway sigrun.h@online.no.
245    10
$a Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial / $c S. Halvorsen, D. Atar, H. Yang, R. De Caterina, C. Erol, D. Garcia, CB. Granger, M. Hanna, C. Held, S. Husted, EM. Hylek, P. Jansky, RD. Lopes, W. Ruzyllo, L. Thomas, L. Wallentin,
520    9_
$a AIMS: The risk of stroke in patients with atrial fibrillation (AF) increases with age. In the ARISTOTLE trial, apixaban when compared with warfarin reduced the rate of stroke, death, and bleeding. We evaluated these outcomes in relation to patient age. METHODS AND RESULTS: A total of 18 201 patients with AF and a raised risk of stroke were randomized to warfarin or apixaban 5 mg b.d. with dose reduction to 2.5 mg b.d. or placebo in 831 patients with ≥2 of the following criteria: age ≥80 years, body weight ≤60 kg, or creatinine ≥133 μmol/L. We used Cox models to compare outcomes in relation to patient age during 1.8 years median follow-up. Of the trial population, 30% were <65 years, 39% were 65 to <75, and 31% were ≥75 years. The rates of stroke, all-cause death, and major bleeding were higher in the older age groups (P < 0.001 for all). Apixaban was more effective than warfarin in preventing stroke and reducing mortality across all age groups, and associated with less major bleeding, less total bleeding, and less intracranial haemorrhage regardless of age (P interaction >0.11 for all). Results were also consistent for the 13% of patients ≥80 years. No significant interaction with apixaban dose was found with respect to treatment effect on major outcomes. CONCLUSION: The benefits of apixaban vs. warfarin were consistent in patients with AF regardless of age. Owing to the higher risk at older age, the absolute benefits of apixaban were greater in the elderly.
650    _2
$a dospělí $7 D000328
650    _2
$a věkové faktory $7 D000367
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a analýza rozptylu $7 D000704
650    _2
$a antikoagulancia $x aplikace a dávkování $x škodlivé účinky $7 D000925
650    _2
$a fibrilace síní $x farmakoterapie $x mortalita $7 D001281
650    _2
$a dvojitá slepá metoda $7 D004311
650    _2
$a rozvrh dávkování léků $7 D004334
650    _2
$a embolie $x mortalita $x prevence a kontrola $7 D004617
650    _2
$a inhibitory faktoru Xa $x aplikace a dávkování $x škodlivé účinky $7 D065427
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a krvácení $x chemicky indukované $x mortalita $7 D006470
650    _2
$a lidé $7 D006801
650    _2
$a Kaplanův-Meierův odhad $7 D053208
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a pyrazoly $x aplikace a dávkování $x škodlivé účinky $7 D011720
650    _2
$a pyridony $x aplikace a dávkování $x škodlivé účinky $7 D011728
650    _2
$a rizikové faktory $7 D012307
650    _2
$a cévní mozková příhoda $x mortalita $x prevence a kontrola $7 D020521
650    _2
$a výsledek terapie $7 D016896
650    _2
$a warfarin $x aplikace a dávkování $7 D014859
650    _2
$a mladý dospělý $7 D055815
655    _2
$a srovnávací studie $7 D003160
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Atar, Dan $u Department of Cardiology B, Oslo University Hospital, Oslo 0407, Norway Institute of Clinical Medicine, University of Oslo, Norway. $7 gn_A_00009712
700    1_
$a Yang, Hongqiu $u Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA.
700    1_
$a De Caterina, Raffaele $u G. D'Annunzio Università - Chieti and Fondazione Toscana G. Monasterio, Pisa, Italy.
700    1_
$a Erol, Cetin $u Faculty of Medicine, Ankara University, Ankara, Turkey.
700    1_
$a Garcia, David $u Division of Hematology, University of Washington, Seattle, WA, USA.
700    1_
$a Granger, Christopher B $u Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA.
700    1_
$a Hanna, Michael $u Bristol-Myers Squibb, Princeton, NJ, USA.
700    1_
$a Held, Claes $u Department of Medical Sciences, Cardiology, and Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden.
700    1_
$a Husted, Steen $u Medical Department, Hospital Unit West, Herning/Holstbro, Denmark.
700    1_
$a Hylek, Elaine M $u Boston University Medical Center, Boston, MA, USA.
700    1_
$a Jansky, Petr $u Cardiovascular Centre, University Hospital Motol, Prague, Czech Republic.
700    1_
$a Lopes, Renato D $u Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA.
700    1_
$a Ruzyllo, Witold $u National Institute of Cardiology, Warsaw, Poland.
700    1_
$a Thomas, Laine $u Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA.
700    1_
$a Wallentin, Lars $u Department of Medical Sciences, Cardiology, and Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden.
773    0_
$w MED00009622 $t European heart journal $x 1522-9645 $g Roč. 35, č. 28 (2014), s. 1864-72
856    41
$u https://pubmed.ncbi.nlm.nih.gov/24561548 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20150709 $b ABA008
991    __
$a 20150729122013 $b ABA008
999    __
$a ok $b bmc $g 1083903 $s 906559
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2014 $b 35 $c 28 $d 1864-72 $i 1522-9645 $m European heart journal $n Eur Heart J $x MED00009622
LZP    __
$a Pubmed-20150709

Najít záznam

Citační ukazatele

Možnosti archivace